ATE187062T1 - Formulierungen zum suspendieren: von proteine und peptiden - Google Patents

Formulierungen zum suspendieren: von proteine und peptiden

Info

Publication number
ATE187062T1
ATE187062T1 AT96920358T AT96920358T ATE187062T1 AT E187062 T1 ATE187062 T1 AT E187062T1 AT 96920358 T AT96920358 T AT 96920358T AT 96920358 T AT96920358 T AT 96920358T AT E187062 T1 ATE187062 T1 AT E187062T1
Authority
AT
Austria
Prior art keywords
peptides
proteins
beneficial agent
suspension formulations
suspension
Prior art date
Application number
AT96920358T
Other languages
English (en)
Inventor
James B Eckenhoff
Leslie A Holladay
John Joseph Leonard Jr
Iris K M Leung
Sally A Tao
Judy A Magruder
John P Carr
Jeremy Wright
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE187062T1 publication Critical patent/ATE187062T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT96920358T 1995-06-07 1996-05-22 Formulierungen zum suspendieren: von proteine und peptiden ATE187062T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/475,238 US5904935A (en) 1995-06-07 1995-06-07 Peptide/protein suspending formulations

Publications (1)

Publication Number Publication Date
ATE187062T1 true ATE187062T1 (de) 1999-12-15

Family

ID=23886776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96920358T ATE187062T1 (de) 1995-06-07 1996-05-22 Formulierungen zum suspendieren: von proteine und peptiden

Country Status (14)

Country Link
US (2) US5904935A (de)
EP (1) EP0831773B1 (de)
JP (2) JPH11506730A (de)
KR (1) KR100460653B1 (de)
CN (1) CN1138528C (de)
AT (1) ATE187062T1 (de)
AU (1) AU706318B2 (de)
CA (1) CA2220871C (de)
DE (1) DE69605417T2 (de)
DK (1) DK0831773T3 (de)
ES (1) ES2139360T3 (de)
FI (1) FI119464B (de)
NZ (1) NZ308843A (de)
WO (1) WO1996040049A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
EP0679088B1 (de) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonale abgabe von aktiven fragmenten des parathormons
ATE416755T1 (de) 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
WO1999055310A1 (en) 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
HK1038508B (en) * 1998-09-09 2006-06-30 Alza Corporation Dosage form comprising liquid formulation
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
CA2361424C (en) * 1999-02-08 2009-04-28 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
AU2001238540A1 (en) 2000-02-24 2001-09-03 Monsanto Technology Llc Non-aqueous injectable formulations for extended release of somatotropin
US6992065B2 (en) 2000-04-19 2006-01-31 Genentech, Inc. Sustained release formulations
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2001271491A1 (en) 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) * 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US20020114843A1 (en) 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
ATE427760T1 (de) * 2001-02-23 2009-04-15 Genentech Inc Erodierbare polymere zur injektion
NZ530700A (en) * 2001-06-21 2009-02-28 Altus Pharmaceuticals Inc Spherical protein particles and methods of making and using them
JP4460892B2 (ja) * 2001-06-21 2010-05-12 ジェネンテック インコーポレイテッド 徐放性組成物
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
WO2003105803A1 (en) * 2002-06-17 2003-12-24 Alza Corporation Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
MXPA05006604A (es) * 2002-12-19 2006-05-25 Alza Corp Geles de una sola fase, no acuosos, estables, y formulaciones de los mismos para el suministro desde un aparato implantable.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004012081T2 (de) * 2003-03-31 2009-03-19 Intarcia Therapeutics, Inc., Emeryville Osmotische pumpe mit mitteln zum ableiten des innendrucks
TW200509999A (en) * 2003-03-31 2005-03-16 Alza Corp Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
DK1635875T3 (da) 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
JP5628467B2 (ja) * 2003-06-26 2014-11-19 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 生体分解性徐放性ドラッグデリバリーシステム
JP2007504215A (ja) 2003-09-03 2007-03-01 バイオフォームズ 生体分子を急速に結晶化するための方法及び装置
AU2004287402A1 (en) * 2003-10-31 2005-05-19 Alza Corporation Osmotic pump with self-retaining, fast-start membrane plug
PL379736A1 (pl) * 2003-11-06 2006-11-13 Alza Corporation Modułowy reduktor prędkości wchłaniania do stosowania z wszczepianą pompą osmotyczną
US8617613B2 (en) 2004-04-15 2013-12-31 Alkermes Pharma Ireland Limited Polymer-based sustained release device
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20060029551A1 (en) * 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
US7655254B2 (en) * 2005-02-03 2010-02-02 Intarcia Therapeutics, Inc. Implantable device for continuous delivery of interferon
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7759312B2 (en) 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
CN101193626A (zh) * 2005-03-11 2008-06-04 益德威士医药股份有限公司 奥曲肽的受控释放制剂
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
EP2359808B1 (de) * 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotisches Verabreichungssystem mit Kolbenanordnung
WO2008133908A2 (en) * 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
CA2685397C (en) 2007-04-27 2016-07-26 Endo Pharmaceuticals Solutions Inc. Implant device release agents and methods of using same
JP5496082B2 (ja) * 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
CA2726861C (en) * 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2729139C (en) 2008-06-25 2016-07-26 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
EP2303226B1 (de) 2008-06-25 2016-03-23 Endo Pharmaceuticals Solutions Inc. Verlängerte freisetzung von exenatid und anderen polypeptiden
PE20110543A1 (es) 2008-08-15 2011-08-04 Ironwood Pharmaceuticals Inc Formulacion solida oral que comprende linaclotida, cation de calcio y leucina
CN102281865B (zh) * 2008-10-15 2017-04-05 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
EP2376522A4 (de) 2008-11-16 2013-12-25 Univ Texas Niederviskose hochkonzentrierte suspensionen
EP2461818B1 (de) 2009-08-03 2018-10-17 Incube Labs, Llc Schluckbare kapsel und verfahren zur stimulation der inkretinproduktion im darmtrakt
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US8759284B2 (en) 2009-12-24 2014-06-24 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
EP2603232B1 (de) 2010-08-11 2019-09-25 Ironwood Pharmaceuticals, Inc. Stabile linaclotidformulierungen
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9149617B2 (en) 2010-12-23 2015-10-06 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809271B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8764733B2 (en) 2010-12-23 2014-07-01 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) * 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
MX347354B (es) 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732865A (en) * 1971-01-13 1973-05-15 Alza Corp Osmotic dispenser
US3833725A (en) * 1972-12-08 1974-09-03 Syntex Corp Dialkylated glycol compositions and medicament preparations containing same
US4036954A (en) * 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
US4180560A (en) * 1976-10-26 1979-12-25 Syntex Corporation Inert core implant pellet
US4215691A (en) * 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
US4237885A (en) * 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
US4389414A (en) * 1981-05-11 1983-06-21 Syntex (U.S.A.) Inc. Prostaglandin compositions
US4507281A (en) * 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
US4475916A (en) * 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
EP0092918B1 (de) * 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Mittel mit verzögerter Freigabe
US4483849A (en) * 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
ATE26584T1 (de) * 1983-07-01 1987-05-15 Battelle Memorial Institute In-vivo abbaubares polypeptid und dessen anwendung zur verzoegerten freigabe von medikamenten.
US4855134A (en) * 1983-10-14 1989-08-08 Sumitomo Pharmaceuticals Company, Limited Sustained-release preparation
GB2155889B (en) * 1984-03-21 1988-03-02 Alza Corp Dispenser-capsule
US5032572A (en) * 1984-07-18 1991-07-16 Medical College Of Ohio Polymers containing cross-linked azo bonds, which polymers are useful for releasing therapeutic agents into the lower gastrointestinal tract
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
JPS63281299A (ja) * 1987-05-13 1988-11-17 Hitachi Ltd 連想メモリ装置
EP0294160A1 (de) * 1987-06-02 1988-12-07 Schering Corporation Behandlung von chronischer Hepatitis B mit einer Mischung menschlicher rekombinanter Alpha- und Gamma-Interferone
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
IT1222734B (it) * 1987-09-25 1990-09-12 Scalvo S P A Formulaziopne farmaceutiche e forme di dosaggio per la somminaistarzione rettale di calcitonina
US4855141A (en) * 1988-03-25 1989-08-08 Alza Corporation Device comprising means for protecting and dispensing fluid sensitive medicament
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
EP0374120A3 (de) * 1988-12-13 1991-07-31 Monsanto Company Zusammensetzung mit kontrollierter Wirkstoffabgabe von Polypeptiden
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
JP2514249B2 (ja) * 1989-05-23 1996-07-10 帝人株式会社 安定化されたカルシトニン類医薬組成物
US5100392A (en) * 1989-12-08 1992-03-31 Biosynthesis, Inc. Implantable device for administration of drugs or other liquid solutions
IT1242642B (it) * 1990-04-17 1994-05-16 Alfa Wassermann Spa Formulazioni iniettabili contenenti naproxen sale sodico.
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5236707A (en) * 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
JP3730667B2 (ja) * 1991-12-27 2006-01-05 武田薬品工業株式会社 注射用組成物
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5221278A (en) * 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
WO1995010989A1 (en) * 1993-10-19 1995-04-27 Scimed Life Systems, Inc. Intravascular stent pump
ATE225647T1 (de) * 1994-06-13 2002-10-15 Alza Corp Dosierungsform zur verabreichung von flüssige arzneimittel formulierung
WO1999008832A1 (de) * 1997-08-20 1999-02-25 Mikron Sa Agno Vorrichtung zum bewegen und positionieren eines gegenstandes in einer ebene

Also Published As

Publication number Publication date
EP0831773A1 (de) 1998-04-01
NZ308843A (en) 2000-01-28
CN1187119A (zh) 1998-07-08
JP2009057389A (ja) 2009-03-19
CN1138528C (zh) 2004-02-18
KR19990022486A (ko) 1999-03-25
US5904935A (en) 1999-05-18
AU706318B2 (en) 1999-06-17
KR100460653B1 (ko) 2005-08-05
DE69605417T2 (de) 2000-03-23
AU5869496A (en) 1996-12-30
FI974429L (fi) 1997-12-05
ES2139360T3 (es) 2000-02-01
FI974429A0 (fi) 1997-12-05
EP0831773B1 (de) 1999-12-01
WO1996040049A1 (en) 1996-12-19
DK0831773T3 (da) 2000-05-08
CA2220871A1 (en) 1996-12-19
US5972370A (en) 1999-10-26
FI119464B (fi) 2008-11-28
CA2220871C (en) 2011-02-08
JPH11506730A (ja) 1999-06-15
DE69605417D1 (de) 2000-01-05

Similar Documents

Publication Publication Date Title
ATE187062T1 (de) Formulierungen zum suspendieren: von proteine und peptiden
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
IL113812A (en) Copolymer-1 pharmaceutical compositions containing it and its use
MY125556A (en) Aqueous formulations of peptide
DE69430635D1 (de) Loteprednoletabonat-suspension
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
IL109403A0 (en) Oral drug delivery compositions and methods
MX9700223A (es) Composicion farmaceutica para la liberacion controlada de moguisteina en una suspension liquida.
DE69522343D1 (de) Gelstiftzusammensetzung enthaltend gebildner angereichert in optisch aktiver form
MX9801732A (es) Anticuerpos anti-cd4 recombinantes para la terapia a humanos.
MY128654A (en) Liquid pharmaceutical composition containing an erythropoietin derivative
GEP19981289B (en) Method for Preparing Preserved Medicinal Means Containing Human Protein and Medicinal Means
IL172835A0 (en) A composition for stabilizing active protein ingredients in pharmaceutical composition containing at least 2 amino acids
DE69433723D1 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
DK0749317T3 (da) Terapeutiske anvendelser af dimerprodukter af baktericidt/permeabilitetsforøgende protein
DE69324006D1 (de) Zubereitungen von hyaluronsaeure mit niedrigem molekulargewicht zur foerderung der knochenbildung
PT999843E (pt) Composicoes farmaceuticas contendo vitamina d e calcio, sua preparacao e uso terapeutico
IL98917A0 (en) Piperidyl ethers and thioethers and their use as inhibitors of cholesterol biosynthesis
BE1014502A5 (fr) Compositions pharmaceutiques.
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
DE69524971D1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
MX9709907A (es) Formulaciones de suspension de peptido/proteina.
SE8500102L (sv) Forfarande for mikrofloraavlossning

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties